Philip Robinson

Age-related differences in SARS-CoV-2 binding factors: An explanation for reduced susceptibility to severe COVID-19 among children?

Thomas Abrehart, Randy Suryadinata, Conor McCafferty, Jonathan Jacobson, Vera Ignjatovic, Phil Robinson, Nigel W Crawford, Paul Monagle, Kanta Subbarao, Catherine Satzke, Danielle Wurzel

Journal article  |  2022  |  PAEDIATRIC RESPIRATORY REVIEWS

CONTEXT: In contrast with other respiratory viruses, children infected with SARS-CoV-2 are largely spared from severe COVID-19. OB..

Heparin Inhibits SARS-CoV-2 Replication in Human Nasal Epithelial Cells

Leo Yi Yang Lee, Randy Suryadinata, Conor McCafferty, Vera Ignjatovic, Damian FJ Purcell, Phil Robinson, Craig J Morton, Michael W Parker, Gary P Anderson, Paul Monagle, Kanta Subbarao, Jessica A Neil

Journal article  |  2022  |  VIRUSES-BASEL

SARS-CoV-2 is the causative agent of the COVID-19 pandemic. Vaccination, supported by social and public health measures, has prove..

Clinical Utility of Bronchoalveolar Lavage in Pediatric Oncology Patients

Shivanthan Shanthikumar, Samuel Colenutt, Theresa Cole, Rachel Conyers, Tom Rozen, Jo Harrison, Philip Robinson, Gabrielle M Haeusler

Journal article  |  2022  |  PEDIATRIC INFECTIOUS DISEASE JOURNAL

BACKGROUND: Lower airway sampling is important in the assessment of lower respiratory tract infection in children with cancer or p..

The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial.

Stephen M Stick, Alexia Foti, Robert S Ware, Harm AWM Tiddens, Barry S Clements, David S Armstrong, Hiran Selvadurai, Andrew Tai, Peter J Cooper, Catherine A Byrnes, Yvonne Belessis, Claire Wainwright, Adam Jaffe, Philip Robinson, Lisa Saiman, Peter D Sly, undefined COMBAT CF Study Group

Journal article  |  2022  |  Lancet Respir Med

BACKGROUND: Structural lung disease and neutrophil-dominated airway inflammation is present from 3 months of age in children diagn..

The effect of inhaled hypertonic saline on lung structure in children aged 3-6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial.

Harm AWM Tiddens, Yuxin Chen, Eleni-Rosalina Andrinopoulou, Stephanie D Davis, Margaret Rosenfeld, Felix Ratjen, Richard A Kronmal, Karen D Hinckley Stukovsky, Alison Dasiewicz, Stephen Michael Stick, undefined SHIP-CT Study Group

Journal article  |  2022  |  Lancet Respir Med

BACKGROUND: In the Saline Hypertonic in Preschoolers (SHIP) study, inhaled 7% hypertonic saline improved the lung clearance index ..

Persistent pleuritic chest pain in a patient with cystic fibrosis

Stefanie Louey, Shivanthan Shanthikumar, Moya Vandeleur, Amanda Gwee, Phil Robinson

Journal article  |  2022  |  BREATHE

Pleural effusion is rare in cystic fibrosis. Infection leading to pleural effusion is likely to be polymicrobial, including contri..

Reducing exacerbations in children and adults with primary ciliary dyskinesia using erdosteine and/or azithromycin therapy (REPEAT trial): study protocol for a multicentre, double-blind, double-dummy, 2x2 partial factorial, randomised controlled trial

Anne B Chang, Lucy C Morgan, Emma L Duncan, Mark D Chatfield, Andre Schultz, Paul J Leo, Gabrielle B McCallum, Aideen M McInerney-Leo, Steven M McPhail, Yuejen Zhao, Catherine Kruljac, Heidi C Smith-Vaughan, Peter S Morris, Julie M Marchant, Stephanie T Yerkovich, Anne L Cook, Danielle Wurzel, Lesley Versteegh, Hannah O'Farrell, Margaret S McElrea, et al.

Journal article  |  2022  |  BMJ OPEN RESPIRATORY RESEARCH

INTRODUCTION: Primary ciliary dyskinesia (PCD) is a rare, progressive, inherited ciliopathic disorder, which is incurable and freq..

Fissure adjacent partial lobe atelectasis in primary ciliary dyskinesia

Loraine Fabri, Shivanthan Shanthikumar, Katelyn Tadd, Lucy Morgan, Andre Schultz, Philip Robinson

Journal article  |  2022  |  JOURNAL OF PAEDIATRICS AND CHILD HEALTH

AIM: Establishing the underlying cause in a child with chronic suppurative lung disease (CSLD) allows for targeted treatment and s..

Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.

Sivagurunathan Sutharsan, Edward F McKone, Damian G Downey, Jamie Duckers, Gordon MacGregor, Elizabeth Tullis, Eva Van Braeckel, Claire E Wainwright, Danie Watson, Neil Ahluwalia, Bote G Bruinsma, Christopher Harris, Anna P Lam, Yiyue Lou, Samuel M Moskowitz, Simon Tian, Jason Yuan, David Waltz, Marcus A Mall, undefined VX18-445-109 study group

Journal article  |  2022  |  Lancet Respir Med

BACKGROUND: Elexacaftor plus tezacaftor plus ivacaftor is a triple-combination cystic fibrosis transmembrane conductance regulator..

O049 Sleep quality and its impact on children with primary ciliary dyskinesia

I Ewert, P Robinson, A Adams, M Vandeleur

Journal article  |  2021  |  SLEEP Advances

Abstract Background PCD is a rare, progressive disease resulting in upper resp..